ClinicalTrials.gg

Program

KRAS G12D Inhibitor VS-7375

Also written as “GFH375”, “VS-7375” and “GFH375 + Cetuximab”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Pancreatic Neoplasms · Colorectal Neoplasms, led by 2 companies.

Furthest: phase 3, since Nov 20, 202512 company-led studies, 11 open or runningNext primary completion: Apr 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Genfleet Therapeutics (Shanghai)87 open or runningphase 3since Nov 20, 2025Jul 8, 2024Apr 30, 2027phase 2 · NCT07554859
Verastem44 open or runningphase 2since May 26, 2025May 26, 2025Jun 2027phase 2 · NCT07659795

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 8, 2024First study: phase 2 study in KRAS G12D MutationsNew to Genfleet Therapeutics (Shanghai)Genfleet Therapeutics (Shanghai) · NCT06500676 · 407 planned · China
  2. May 26, 2025Verastem’s first study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to VerastemVerastem · NCT07020221 · 616 planned · United States, Australia, France and more
  3. Jun 3, 2025Phase 2 study in Pancreatic NeoplasmsGenfleet Therapeutics (Shanghai) · NCT07026916
  4. Nov 14, 2025Phase 2 study in Colorectal NeoplasmsGenfleet Therapeutics (Shanghai) · NCT07259590 · 126 planned · China
  5. Nov 20, 2025Phase 3 study in Pancreatic NeoplasmsPhase 3 reachedGenfleet Therapeutics (Shanghai) · NCT07262567 · 320 planned · China
  6. Apr 21, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungGenfleet Therapeutics (Shanghai) · NCT07554859 · 90 planned · China
  7. May 26, 2026Phase 2 study in Pancreatic NeoplasmsVerastem · NCT07644559 · 185 planned · United States, Australia, Canada and more
  8. Jun 15, 2026Phase 3 study in Carcinoma, Non-Small-Cell LungGenfleet Therapeutics (Shanghai) · NCT07668752 · 300 planned · China
  9. Jun 15, 20262 phase 2 studiesVerastem · NCT07659795, NCT07659782
  10. Aug 10, 2026Phase 2 study in Pancreatic NeoplasmsGenfleet Therapeutics (Shanghai) · NCT07784374 · 120 planned · China
  11. Oct 18, 2026Phase 3 study in Colorectal NeoplasmsGenfleet Therapeutics (Shanghai) · NCT07913360 · 368 planned

Ahead

  1. Apr 30, 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungGenfleet Therapeutics (Shanghai) · NCT07554859
  2. Jun 2027Primary completion: phase 2 study in Colorectal NeoplasmsVerastem · NCT07659795
  3. Jun 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungVerastem · NCT07659782
  4. Jun 2027Primary completion: phase 2 study in Pancreatic NeoplasmsVerastem · NCT07644559

TargetBeta

KRAS →read by rule
“An orally bioavailable non-covalent small molecule inhibitor of both the active, guanosine triphosphate (GTP)-bound form and the inactive, guanosine diphosphate (GDP)-bound form of the oncogenic KRAS substitution mutation G12D, ”NCIt, by rule

Other programs on KRAS

ProgramCompanyFurthest phaseStudies
sotorasibruleAmgenphase 328
adagrasibruleBristol-Myers Squibbphase 316
olomorasibEli Lillyphase 316
divarasibHoffmann-La Rochephase 313
glecirasibruleAllist Pharmaceuticalsphase 312
calderasibMerckphase 312
daraxonrasibruleRevolution Medicinesphase 310
garsorasibruleInventisBiophase 38
KRAS G12D Inhibitor HRS-4642Jiangsu HengRui Medicinephase 37
zoldonrasibruleRevolution Medicinesphase 36
HRS-7058Jiangsu HengRui Medicinephase 36
opnurasibruleNovartisphase 35

Studies

All 12 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07913360Colorectal Neoplasms3Not yet recruitingGenfleet Therapeutics (Shanghai)Nov 2028368
NCT07784374Pancreatic Neoplasms · China2RecruitingGenfleet Therapeutics (Shanghai)Aug 31, 2028120
NCT07668752Carcinoma, Non-Small-Cell Lung · China3RecruitingGenfleet Therapeutics (Shanghai)Jun 30, 2030300
NCT07659795Colorectal Neoplasms · United States, Australia, France and more2RecruitingVerastemJun 2027150
NCT07659782Carcinoma, Non-Small-Cell Lung · United States, Australia, Belgium and more2RecruitingVerastemJun 2027105
NCT07644559Pancreatic Neoplasms · United States, Australia, Canada and more2RecruitingVerastemJun 2027185
NCT07554859Carcinoma, Non-Small-Cell Lung · China2Not yet recruitingGenfleet Therapeutics (Shanghai)Apr 30, 202790
NCT07262567Pancreatic Neoplasms · China3RecruitingGenfleet Therapeutics (Shanghai)Jun 2027320
NCT07259590Colorectal Neoplasms · China2RecruitingGenfleet Therapeutics (Shanghai)Jul 2027126
NCT07026916Pancreatic Neoplasms2WithdrawnGenfleet Therapeutics (Shanghai)Aug 20270
NCT07020221Carcinoma, Non-Small-Cell Lung · United States, Australia, France and more2RecruitingVerastemDec 2028616
NCT06500676KRAS G12D Mutations · China2RecruitingGenfleet Therapeutics (Shanghai)Jul 31, 2028407

How it is read

Names in the registry

  • “GFH375”, 7 entries
  • “VS-7375”, 4 entries
  • “GFH375 + Cetuximab”, 1 entry
  • “ArmA:GFH375”, 1 entry
  • “Arm B:GFH375”, 1 entry

Codes read as this program: GFH375.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.